Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Must Reads In Melanoma
Melanoma for January/February 2016
Cancers Among Nordic Twins, Assessing excess familial risk
FDA Approves Expanded Keytruda Indication, Now first-line for unresectable or metastatic melanoma
Melanoma for November/December 2015
Autoimmune Comorbidities in Advanced Melanoma, Assessing the efficacy and safety of ipilimumab
FDA Approves Opdivo for Advanced Melanoma, Monotherapy for BRAF wild-type melanoma
Genetic Evolution From Lesion to Melanoma, Tracing a variety of trajectories
FDA Approves Cotellic/Zelboraf Combination, Used in treatment of unresectable or metastatic melanoma
FDA Approves New Indication for Yervoy, Approved for cutaneous melanoma
Melanoma for September/October 2015
GM-CSF and Peptide Vaccination in Melanoma, Does either improve survival?
Ipilimumab in Melanoma, Do immune-related adverse events affect OS and TTF?
Melanoma for July/August 2015
Sentinel Lymph Node Metastases in Melanoma, Can the prognostic model be improved?
Ipilimumab in Melanoma, A study of safe infusion rates
Citrus Consumption in Melanoma, Does it increase risk?